Maximum quantity allowed is 999
CAS RN: 2590-41-2 | Product Number: D5471
6-Dehydronandrolone Acetate
Purity: >98.0%(HPLC)
- 17β-Acetoxyestra-4,6-dien-3-one
Size | Unit Price | Hyderabad | Japan* | Quantity |
---|---|---|---|---|
1G |
₹4,100.00
|
3 | 14 |
|
5G |
₹11,000.00
|
2 | 2 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
Product Number | D5471 |
Purity / Analysis Method | >98.0%(HPLC) |
Molecular Formula / Molecular Weight | C__2__0H__2__6O__3 = 314.43 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
Packaging and Container | 1G-Glass Bottle with Plastic Insert (View image) |
CAS RN | 2590-41-2 |
Reaxys Registry Number | 3121674 |
MDL Number | MFCD00271529 |
Appearance | White to Orange to Green powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Melting point | 106.0 to 110.0 °C |
Specific rotation [a]20/D | -37.0 to -40.0 deg(C=1,CHCl3) |
Melting Point | 108 °C |
Specific Rotation | -38° (C=1,CHCl3) |
Maximum Absorption Wavelength | 283(MeOH) nm |
Pictogram | |
Signal Word | Warning |
Hazard Statements | H361 : Suspected of damaging fertility or the unborn child. |
Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
References
- Fulvestrant: From the Laboratory to Commercial-Scale Manufacture
- Development of a Catalytic Cuprate 1,6-Conjugate Dienone Addition Process for the Manufacture of Fulvestrant EAS, a Key Intermediate in the Synthesis of Fulvestrant
- An alternative synthesis of the breast cancer drug fulvestrant (Faslodex): catalyst control over C-C bond formation
Articles/Brochures
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.